A rare case describes onset of myasthenia gravis, neuromyelitis optica, and anti-N-methyl-D-aspartate receptor in one woman, ...

Women's neurology is an evolving field dedicated to incorporating sex and gender considerations into neurological education, research and care. Despite some ...

You know that tiny eye twitch that shows up right when your inbox explodes or after your third cup of coffee? We’ve all been ...

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...

Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and ...

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

The thought 'no-one is accountable' for the death of Helen Holland, the 81-year-old hit by the Duchess of Edinburgh's royal ...

Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the ...

Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life ...

The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...